We found that treating BC cells (MCF7) with the HMG-CoA reductase inhibitor, atoravastatin/Lipitor resulted in a dose-dependent restoration of IL-2 production, a measure of NKT cell function (Figure 7A,C). The gene discussed is HMGCR; the disease is breast cancer.